TKM 080301 for Primary or Secondary Liver Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01437007 |
Recruitment Status :
Completed
First Posted : September 20, 2011
Last Update Posted : August 3, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g. colon, pancreas, gastric, breast, ovarian, esophageal cancers, cancer with metastases to the liver.) People who have tumors that can be removed by surgery live longer than those whose cancer cannot be removed. Chemotherapy can shrink some tumors in the liver, which also helps people to live longer, and sometimes chemotherapy can shrink tumors enough that they can be removed by surgery. However, most chemotherapy drugs do not work well on tumors in the liver. In this study we are testing a new drug, TKM-080301, given directly into the cancer blood supply in the liver circulation, to see if it will cause tumors to shrink.
Objectives:
- To test the safety and effectiveness of TKM-080301 for cancer in the liver that has not responded to standard treatments.
Eligibility:
- Individuals at least 18 years of age who have inoperable cancer that has started in or spread to the liver.
Design:
- Participants will be screened with a medical history and physical exam. They will also have blood tests, and imaging studies.
- Participants will have a liver angiogram (type of X-ray study) to look at the blood flow in the liver and to place a catheter for delivery of the TKM080301.
- Participants will have a single dose of TKM-080301 given directly into the liver. After the drug has been given, the catheter will be removed. They will have frequent blood tests and keep a diary to record side effects.
- Participants may have two more doses, each dose given 2 weeks apart. {Before each dose, participants will have another angiogram and catheter placement.}They may also have liver biopsies to study the tumors.
- Two weeks after the third treatment (one full course), participants will have a physical exam, blood tests, and imaging studies. If the tumor is shrinking, they may have up to three more courses of the study drug.
- Participants will have follow up visits every 3 months for 2 years after the last course and then every 6 months as required.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colorectal Cancer With Hepatic Metastases Pancreas Cancer With Hepatic Metastase Gastric Cancer With Hepatic Metastase Breast Cancer With Hepatic Metastase Ovarian Cancer With Hepatic Metastase | Drug: TKM-080301 | Phase 1 |
BACKGROUND:
- Metastatic liver disease is a life-limiting factor for patients with a variety of cancers. For
unresectable liver metastases, the 5-year survival is < 5%.
- For selected histologies the 5-year survival of resectable hepatic metastases ranges from 20-60%, suggesting that control of liver metastases could result in prolonged survival.
- Phase I through III trials have shown that Hepatic Arterial Infusion (HAI) is safe. However, agents used thus far in HAI have limited efficacy.
- TKM-080301 is a lipid nanoparticle (LNP) formulation containing siRNA against the PLK1 (polo-like kinase-1) gene product. More specifically, TKM-080301 is a type of LNP formulation, referred to as SNALP (Stable Nucleic Acid Lipid Particles). PLK1 has been validated as a molecular target and a prognostic factor in a variety of cancers. Inhibition of PLK1 activity in proliferating cancer cells rapidly induces mitotic arrest and apoptosis.
- This study will offer HAI with TKM-080301 to patients with unresectable and/or life threatening primary liver cancer or liver metastases.
OBJECTIVES:
Primary Objective:
- To evaluate feasibility of administering TKM-080301 via HAI and to characterize the pharmacokinetics (PK) and pharmacodynamics of TKM-080301 administered by HAI.
Secondary Objectives:
- To establish the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of TKM-080301.
- To evaluate response rate using RECIST, PET and EASL criteria.
- To evaluate the conversion rate from unresectable to resectable disease.
ELIGIBILITY:
- Patients with unresectable colorectal, pancreas, gastric, breast, ovarian and esophageal cancers with hepatic metastases; or primary liver cancer patients who have demonstrated progressive disease following standard of care treatment.
- 18 years old or greater with an ECOG 0-2
- Laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to surgery or chemotherapy.
DESIGN:
- This is a dose escalation phase-I study testing HAI of TKM-080301 for patients with
unresectable colorectal, pancreas, gastric, breast, ovarian and esophageal cancers with hepatic metastases, or primary liver cancers.
- Up to 54 patients who meet eligibility criteria will receive HAI with TKM-080301.
- Initial dose will be 4 mg/m(2); treatment will be given every 2 weeks for up to 12 doses.
- Patients will be evaluated every 6 weeks. Patients whose tumors become resectable will be offered this option; patients who show progressive disease will be taken off treatment. All patients will be followed for survival.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients With Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers With Hepatic |
Study Start Date : | August 26, 2011 |
Actual Primary Completion Date : | June 21, 2012 |
Actual Study Completion Date : | June 21, 2012 |
- To evaluate feasibility of administering TKM-080301 via HAI, and establish MTD and DLT. [ Time Frame: 2 years ]
- Characterize PK & pharmacodynamics of TKM 080301 [ Time Frame: 2 years ]
- Eval biological effects of TKM-080301 on biopsies performed before & after 1 cycle of tx [ Time Frame: 2 years ]
- To evaluate the potential conversion rate from unresectable to resectable disease. [ Time Frame: 2.5 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
-INCLUSION CRITERIA:
- Histologically or cytologically confirmed colorectal, pancreas, gastric, breast, ovarian and esophageal cancers with hepatic metastases, or primary liver cancers (Hepatocellular carcinoma and Cholangiocarcinoma).
- Hepatic disease must be measurable per RECIST Criteria (version 1.1).
-
Hepatic disease should be deemed unresectable as per standard of care criteria.
Note: Evidence of limited unresectable extrahepatic disease on preoperative radiological studies is acceptable if the life-limiting component of progressive disease is in the liver.
-
All patients must have failed to respond to standard regimens or therapies known to provide clinical benefit. For example:
- Patients with metastatic colorectal cancer must have received 5-FU and
leucovorin in combination with either oxaliplatin and/or irinotecan, since level
1 evidence support increase survival with these regimens, compared to 5-FU and leucovorin alone.
- Patients with hepatocellular carcinoma must have received sorafenib, since level 1 evidence support increase survival.
- Greater than or equal to 18 years of age
- Must be able to understand and sign the Informed Consent Document
- Clinical performance status of ECOG less than or equal to 2
- Life expectancy of greater/equal than two months
- Patients of both genders must be willing to practice birth control during and for four months after receiving chemotherapy
-
Hematology:
- Absolute neutrophil count greater than or equal to 1500/mm(3) without the support of filgrastim.
- Platelet count greater than or equal to 100,000/mm(3).
- Hemoglobin greater than or equal to 9.0 g/dl.
-
Chemistry:
- Serum ALT/AST less than or equal to 2.5 times the upper limit of normal.
- Serum Albumin greater than or equal to 3.0 g/dL
- Serum creatinine less than or equal to 1.5 times ULN unless the measured
creatinine clearance is greater than 60 mL/min/1.73 m(2)
- Total bilirubin less than or equal to 1.2 mg/dl
- International Normalized Ratio (INR) less than or equal to 1.5
- Seronegative for HIV antibody
- No chemotherapy or any other investigational drugs within 4 weeks of treatment
- LVEF greater than or equal to 50 percent
- QT/QTc interval less than 450 ms
EXCLUSION CRITERIA:
- Any known brain metastases (prior or current regardless of treatment status)
- Women of child-bearing potential who are pregnant or breastfeeding, because of the potentially dangerous effects of the chemotherapy on the fetus or infant.
- Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune systems, recent myocardial infarction or heart failure (within 6 months of enrollment).
- NYHA greater than or equal to 2
- Childs B or C cirrhosis or with evidence of severe portal hypertension by history, endoscopy, or radiologic studies
- Weight less than 40 kg
- Significant ascites, greater than 1000cc in the absence of peritoneal disease
- Concomitant medical problems that would place the patient at an unacceptable risk for the procedure/drug
- Patient has known hypersensitivity or previous severe reactions to oligonucleotideor lipid-based products, including liposomal drug products (e.g. Doxil) and phospholipid-based products (parenteral nutrition, Intralipid)
- Discretion of the PI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01437007
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Udo Rudloff, M.D. | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT01437007 |
Other Study ID Numbers: |
110240 11-C-0240 |
First Posted: | September 20, 2011 Key Record Dates |
Last Update Posted: | August 3, 2018 |
Last Verified: | October 9, 2012 |
SNALP Regional Therapy Stage IV Disease Adenocarcinoma Unresectable Liver Metastases Colorectal Cancer |
Stomach Cancer Gastric Cancer Breast Cancer Ovarian Cancer Pancreatic Cancer Liver Cancer |
Colorectal Neoplasms Neoplasm Metastasis Ovarian Neoplasms Stomach Neoplasms Pancreatic Neoplasms Neoplasms by Site Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |
Neoplastic Processes Pathologic Processes Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Endocrine System Diseases Gonadal Disorders Stomach Diseases |